Pharmaceutical Technology

OCTOBER 28, 2022

Quality by design (QbD) is a concept introduced into the pharmaceutical regulatory lexicon in 2005. Practising QbD in biosimilar product development. One area in which QbD should be practised is that of biosimilars, also known as follow-on biologics or subsequent entry biologics.

Biosimilars 52

Biosimilars Vaccines Drug Development Documentation 52

pharmaphorum

JANUARY 27, 2023

The recent reversal of China’s “zero Covid” policy, at a time when the country still lacks optimal vaccine coverage, has also created another unknown, in terms of global supply and demand forecasting. About the author Richard Saynor was appointed CEO of Sandoz in 2019, a Novartis generics and biosimilars division.

Packaging 105

Packaging Biosimilars Vaccines 105

Pharmaceutical Technology

JULY 23, 2008

It has boosted anti-tumour research by 60% since 2005, at a cost of $1.6bn, in the hope of increasing the share of company sales attributed to cancer drugs from the current level of 5% “There are a lot of patients that are suffering,” said Pfizer chief executive Jeffrey Kindler.

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceutical Companies Compounding Biosimilars 40

Express Pharma

JULY 10, 2024

India has traced a journey of grit and glory to emerge as a major supplier of generic drugs and vaccines globally. IBER Report 2023 divulges, “The biopharma vaccines (non-COVID alone) market makes a significant daily contribution of approximately $38 million. Today, it is a key player in the global pharma landscape. billion monthly.”

Vaccines 96

Vaccines Drug Development Process Improvement Biosimilars 96

Pharma in Brief

JANUARY 10, 2024

The Guidance was last updated in 2005. It now contemplates IT platforms ( e.g. , social media) and applies to drugs for use in humans as well as medical devices, natural health products, biologics, vaccines, and animal health products. Rare disease strategy. mL formulation in Canada”.

Drug Pricing 52

Drug Pricing Documentation Biosimilars Vaccines 52

PharmaShots

APRIL 13, 2023

The company also granted exclusive marketing rights to Meda for Cibacen and Cibadrex in major EU markets for $0.13B In the year 2005, Bayer’s sales depicted an increase of 18%, attributable mainly due to its consumer health business acquired from Roche Abbott achieved a total revenue of $1.4B compared to 2015. to the total revenue.

Biosimilars 40

Biosimilars Vaccines Pharmaceutical Companies Pharmaceutical Companies 40